SCHEMBL3259592

SCHEMBL3259592

Cc1cccc2c(-c3nc4c(cc3F)c(NC(=O)c3ccc(F)cc3)nn4C(=O)c3ccc(F)cc3)cnn12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.38
ALDH1A1 P00352 5/20 0.38
ELANE P08246 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CSNK1D P48730 1/20 0.36
CSNK1E P49674 1/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
IDO1 P14902 1/20 0.34
KDM4E B2RXH2 3/20 0.34
MAPT P10636 2/20 0.34
HTT P42858 2/20 0.34
MAPK1 P28482 1/20 0.34
ATM Q13315 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PPARG P37231 1/20 0.34
NCOA2 Q15596 1/20 0.34
NCOA1 Q15788 1/20 0.34
NCOA3 Q9Y6Q9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265027 0.83 LMNA (0.41) NPC1ALDH1A1MEN1KMT2ARAB9A
SCHEMBL7955204 0.76 ATM (0.39) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL8045946 0.75 NPSR1 (0.34) NPC1ALDH1A1MEN1KMT2ARAB9A
SCHEMBL13099648 0.74 FGFR1 (0.43) NPC1ALDH1A1MEN1KMT2AKDM4E
SCHEMBL3261020 0.69 MAPK1 (0.43) NPC1ALDH1A1RAB9AKDM4EMAPK1
SCHEMBL3265538 0.69 GRM5 (0.43)
SCHEMBL13099704 0.67 CDK2 (0.42) NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E
SCHEMBL8043059 0.66 ALDH1A1 (0.39) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL3263536 0.66 GSK3B (0.52)
SCHEMBL7950685 0.66 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2KDM4EMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME MAP3K20, MAP3K3, MAP3K1 NPC1 994/4885ALDH1A1 2584/4885ELANE 3164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.